Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.52 |
| ▸ | DPYD | Q12882 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HBB | P68871 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7520778 | 0.84 | MEN1 (0.43) | ATAD2DPYDMAPTGAAALDH1A1 | |
| SCHEMBL887700 | 0.83 | ATAD2 (0.48) | ATAD2DPYDMAPTGAAALDH1A1 | |
| SCHEMBL8933555 | 0.83 | GAA (0.48) | ATAD2DPYDMAPTGAAALDH1A1 | |
| SCHEMBL17060272 | 0.79 | ATAD2 (0.45) | ATAD2DPYDMAPTGAAALDH1A1 | |
| SCHEMBL7255538 | 0.79 | ATAD2 (0.45) | ATAD2DPYDMAPTGAAALDH1A1 | |
| SCHEMBL22017500 | 0.79 | ATAD2 (0.45) | ATAD2DPYDMAPTGAAALDH1A1 | |
| SCHEMBL16893950 | 0.79 | GAA (0.54) | ATAD2DPYDMAPTGAAALDH1A1 | |
| SCHEMBL22571173 | 0.78 | ATAD2 (0.39) | ATAD2DPYDMAPTGAAALDH1A1 | |
| SCHEMBL7213457 | 0.78 | KDM3B (0.46) | ATAD2MAPTGAAALDH1A1MEN1 | |
| SCHEMBL7598527 | 0.78 | HTR2A (0.45) | ATAD2DPYDMAPTGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0911325-B1 | Method for producing 5-isopropyluracil | SUMIKA FINE CHEMICALS CO LTD (JP) | 2002-04-17 | — | — | EP | claimed |
| US-5914399-A | Method for producing 5-isopropyluracil | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 1999-06-22 | — | — | US | claimed |
| EP-0911325-A1 | Method for producing 5-isopropyluracil | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 1999-04-28 | — | — | EP | claimed |
| JP-7017953-A | — | — | None | — | — | JP | disclosed |
| JP-11189587-A | — | — | None | — | — | JP | disclosed |
| CN-119775260-A | Pyrimidine-2, 4 (1H, 3H) -dione compounds, preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2025-04-08 | — | — | CN | disclosed |
| CN-119424439-A | Uridine Phosphorylase (UPASE) inhibitors for the treatment of liver diseases | 托斯克公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-114450009-B | Uridine Phosphorylase (UPASE) inhibitors for the treatment of liver diseases | 托斯克公司 | 2024-11-26 | — | — | CN | disclosed |
| CN-117597139-A | Uridine phosphorylase inhibitors for preventing or treating drug-induced pulmonary dysfunction | 托斯克公司 | 2024-02-23 | — | — | CN | disclosed |
| US-20230381152-A1 | METHODS FOR TREATING COLON CANCER WITH COMPOSITIONS COMPRISING AMLEXANOX AND IMMUNE CHECKPOINT INHIBITORS | MOONSHOT PHARMA LLC (US) | 2023-11-30 | — | — | US | disclosed |
| EP-3843850-B1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC (US) | 2023-11-15 | — | — | EP | disclosed |
| JP-H0717953-A | PRODUCTION OF 5-ISOPROPYLURACIL | SUMIKA FINE CHEM KK | 1995-01-20 | — | — | JP | disclosed |
| EP-0631783-A1 | Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives | Mitsubishi Chemical Corporation (JP) | 1995-01-04 | — | — | EP | disclosed |
| US-5318972-A | Active against retroviruses, human t-cell leukemia/lymphoma viruses | MITSUBISHI KASEI CORPORATION (JP) | 1994-06-07 | — | — | US | disclosed |
| EP-0449726-A1 | Pyrimidine nucleoside derivative and antiviral agent containing the derivative as active ingredient | Mitsubishi Chemical Corporation (JP) | 1991-10-02 | — | — | EP | disclosed |
| EP-0420763-A2 | 6-Substituted acyclopyrimidine nucleoside derivatives and antiviral agent containing the same as active ingredient thereof | Mitsubishi Chemical Corporation (JP) | 1991-04-03 | — | — | EP | disclosed |
| US-4937233-A | USED AS OINTMENT OR GEL | MTA KOZPONTI KEMIAL KUTATO INTEZETE (HU) | 1990-06-26 | — | — | US | disclosed |
| CN-1034133-A | Accumulate in external antiviral agents in the skin and preparation method thereof | MTA KOEZPONTI KEMIAI KUTATO IN (HU) | 1989-07-26 | — | — | CN | disclosed |
| US-3935184-A | Synthetic polyoxin type nucleosides | SYNTEX (U.S.A.) INC. (US) | 1976-01-27 | — | — | US | disclosed |
| JP-H00717953-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381152-A1 | METHODS FOR TREATING COLON CANCER WITH COMPOSITIONS COMPRISING AMLEXANOX AND IMMUNE CHECKPOINT INHIBITORS | CD274, MYD88, PDCD1LG2 | ATAD2 2049/4885DPYD 833/4885MAPT 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.